Published in Immunotherapy Weekly, February 4th, 2004
"His many years of experience in the field of drug and biologic regulatory law, his knowledge of the FDA, his law practice in Washington, D.C., and his past and current board memberships make Peter very valuable to Favrille as we move towards product commercialization," said John Longenecker, PhD, Favrille's president and chief executive officer.
Favrille is currently conducting Phase II clinical trials with the Company's lead investigational agent,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.